Investors Capital Advisory Services’s Lexicon Pharmaceuticals LXRX Stock Holding History

Investors Capital Advisory Services’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,429	Closed	-$15K	–	751
2014 Q4	$15K	Buy	2,429 +715	+42%	+$5.76K	﹤0.01%	715
2014 Q3	$16K	Hold	1,714	–	–	﹤0.01%	696
2014 Q2	$19K	Buy	+1,714	New	+$18.4K	﹤0.01%	693

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Investors Capital Advisory Services's LXRX Position: Q1 2015 in Review

Investors Capital Advisory Services sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2015, closing a stake of 2,429 shares — an estimated $15K sold.

Investors Capital Advisory Services first reported a position in LXRX in Q2 2014 and held it in 3 quarters. The position peaked at $19K in Q2 2014. 119 funds tracked by Wall St. Rank hold LXRX as of Q1 2015.

Investors Capital Advisory Services reported no remaining Lexicon Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Investors Capital Advisory Services sold 2,429 Lexicon Pharmaceuticals shares in Q1 2015, an estimated $15K.
Investors Capital Advisory Services first reported a position in Lexicon Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Investors Capital Advisory Services's Lexicon Pharmaceuticals position peaked at $19K in Q2 2014.
119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2015.

Based on Investors Capital Advisory Services's 13F filing for Q1 2015, filed 12 May 2015.